Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas

Fig. 1

α-PD-1 effects on tumor-growth of chemically-induced and GEMM-derived SCCs. a Total NS-SNV loads of Kras-driven SCCs, determined by WES analysis. The panel includes four chemically-induced (CCK) and two GEMM-derived (GEK) SCCs, b Scheme for syngeneic tumor generation and drug therapy: After implantation of 1.5 × 104 tumor cells by unilateral dorsolateral subcutaneous injection, tumors grew for 14 days until they reached ≥5 mm diameter. Mice were then treated with control IgGs or α-PD-1 drugs injected intraperitoneally (ip) into the contralateral side, with three drug administrations, each four days apart (considered days 0, 4 and 8). c-f) Tumor growth of the indicated tumor lines with or without α-PD-1 therapy was measured at least every other day from the time of first drug administration. Red arrows indicate timing of drug administration (see Additional file 3: Figure S1 for GEK1428, and CCK62 growth curves), c-e) mean tumor growth of 7–10 mice per arm. ** = p < 0.01 (Fisher’s Exact test)

Back to article page